Biotech Startups

Integrated Dynamics develops high-temperature fermentation technology to produce bio-based chemical intermediates for onshore manufacturing. The company's solutions integrate into new or existing industrial fermentation infrastructure to reduce production costs.

1 investor

Integrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.

1 investor

IntelliSeq provides automated, cloud-based genomic analysis pipelines that take raw sequencing data to structured clinical output across oncology, hereditary disorders, pharmacogenomics, and risk assessment. It serves laboratories and healthcare providers, integrating with LIMS, LIS, and EHR systems.

1 investor

Intensity Therapeutics is a clinical-stage biotech developing intratumoral drug delivery technology that injects therapeutic agents directly into solid tumors to kill cancer cells and trigger a systemic immune response. It targets patients with metastatic cancer as well as presurgical patients seeking to avoid disease recurrence.

1 investor

InterAx Biotech develops computational and structural biology tools for pharmaceutical research and drug discovery, serving biopharmaceutical companies and researchers in drug development.

1 investor

InterCure produces, manufactures, and distributes pharmaceutical-grade cannabis and cannabis-based products for medical use in licensed markets including Israel, the European Union, and Australia, and operates a chain of over 25 licensed pharmacies across Israel, the UK, and Austria that specialize in medical cannabis dispensing.

1 investor

1 investor

Interna develops a molecular delivery platform that transports large molecule therapeutics such as DNA, RNA, and proteins across cell membranes to treat infectious and non-infectious diseases. The company's molecular nano-motor technology harnesses the cell membrane's electric potential to enable intracellular drug delivery for respiratory and other therapeutic applications.

1 investor

LIC is a farmer-owned cooperative that develops and exports dairy genetics for artificial insemination, serving dairy farmers in New Zealand and 20 countries globally to improve herd productivity and profitability.

1 investor

Intervacc develops veterinary vaccines based on recombinant protein fusions. The company's lead product, Strangvac®, prevents strangles in horses, a serious and contagious global disease, and is available on several major European markets.

1 investor

Intragel is developing SRGel, a solvent-free long-acting injectable (LAI) drug delivery platform designed to enable controlled, extended release from a single injection for small molecules, peptides and biologics. The platform aims to extend dosing intervals and reduce injection frequency across multiple therapeutic areas.

1 investor

A biopharmaceutical company developing treatments for psychiatric and neurologic disorders based on research into how therapies affect cellular mechanisms. The company, now part of Johnson & Johnson, focuses on innovative therapies for patients with complex brain-related diseases.

1 investor

Intropic Materials develops a protein-stabilization technology that embeds enzymes into plastics to create self-degrading materials that can be composted or recycled. It targets the plastic waste problem and aims to support a bio-based economy, with additional applications in clean manufacturing and biosensors.

1 investor

Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.

1 investor

Invasive Species Corporation develops biological solutions to control invasive species and resistant pests across agriculture, water management, and environmental sectors. The company combines expertise in microbial discovery and product development to deliver environmentally friendly alternatives to traditional pest management.

1 investor

Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.

1 investor

InvenireX advances molecular diagnostics in life sciences through innovation in biotechnology. The company develops solutions for scientific research and healthcare applications.

1 investor

Inventia Life Science develops 3D cell culture platforms and standardized cell models for drug discovery, cancer research, and toxicity screening. The platform enables reproducible, human-relevant assays for pharmaceutical and biotech research teams.

1 investor

Inventure is a generalist venture capital firm investing primarily in Nordic and Baltic companies across deep tech, consumer, healthtech, AI, and B2B SaaS sectors. Founded in 2005, the firm has backed over 100 portfolio companies.

1 investor

InveriTek provides high-throughput chemical screening using freshwater planarians, detecting systemic toxicity, neurotoxicity, and ecotoxicity through behavioral phenotyping in whole organisms. The service targets pharmaceutical, chemical, and environmental testing markets requiring toxicology assessment.

1 investor

Invictus Therapeutics develops novel insulin analogs and related pump technologies aimed at insulin-dependent diabetic patients, focusing on ultra-rapid, concentrated, room-temperature-stable insulin for next-generation insulin pumps. Its lead candidate is a monomeric insulin formulation with improved pharmacokinetics and extended stability.

1 investor

InvisiShield Technologies develops products designed to prevent respiratory infections from airborne viruses such as COVID-19, influenza, and RSV. The company focuses on protecting people from illnesses caused by respiratory viruses.

1 investor

Invitrall develops long-lasting, disease-representative human skin organoids from reprogrammed human cells, combining cell reprogramming, organoids, and machine learning to create human preclinical models. Its platform supports efficacy and repeated-dose toxicity testing for pharmaceutical and dermocosmetics companies developing skin drugs and cosmetics, as an alternative to animal testing.

1 investor

A company developing in vitro testing methods to assess respiratory sensitization for regulatory compliance in chemical and pharmaceutical industries.

1 investor